Want to cut your energy bills? Here’s how five experts are doing it 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
MORRISVILLE, N.C., March 03, 2017 -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Monday, Mar. 6, at 8 a.m. Eastern Time to provide an update on the SB204 development program. Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (844) 707-0661 (toll-free in the United States and Canada) or +1 (703) 318-2240 (international). The conference ID for the live call is 77470993. A live webcast will be accessible from the Events page of the Company’s website at http://Events.Novan.com. The webcast will be archived on the Company’s website for 90 days following the live call.
About Novan
Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.
For more information, visit the Company’s website at www.Novan.com.
CONTACT: (Investors) Sean Andrews, Senior Director of Investor Relations Novan, Inc. 919-627-6847 [email protected] (Media) Deb Holliday Pascale Communications, LLC 412-877-4519 [email protected]
